Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | cytochrome P450, family 2, subfamily C, polypeptide 19 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Brugia malayi | Cytochrome P450 family protein | Get druggable targets OG5_126582 | All targets in OG5_126582 |
Loa Loa (eye worm) | cytochrome P450 family protein | Get druggable targets OG5_126582 | All targets in OG5_126582 |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Leishmania major | cytochrome p450-like protein | cytochrome P450, family 2, subfamily C, polypeptide 19 | 490 aa | 411 aa | 23.1 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | isocitrate dehydrogenase | 0.0085 | 0.0452 | 0.148 |
Echinococcus multilocularis | tar DNA binding protein | 0.0406 | 0.2759 | 0.9024 |
Trypanosoma brucei | isocitrate dehydrogenase [NADP], mitochondrial precursor, putative | 0.0085 | 0.0452 | 1 |
Onchocerca volvulus | Rap guanine nucleotide exchange factor 1 homolog | 0.0194 | 0.1238 | 1 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.1414 | 1 | 1 |
Echinococcus multilocularis | diuretic hormone 44 receptor GPRdih2 | 0.0447 | 0.3057 | 1 |
Echinococcus granulosus | Ataxin 2 N terminaldomain containing protein | 0.0022 | 0.0003 | 0.001 |
Echinococcus multilocularis | cadherin EGF LAG seven pass G type receptor | 0.0447 | 0.3057 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0406 | 0.2759 | 0.4065 |
Schistosoma mansoni | tar DNA-binding protein | 0.0406 | 0.2759 | 0.4065 |
Loa Loa (eye worm) | RNA binding protein | 0.0406 | 0.2759 | 0.2759 |
Schistosoma mansoni | NADP-specific isocitrate dehydrogenase | 0.0085 | 0.0452 | 0.0667 |
Schistosoma mansoni | hypothetical protein | 0.0967 | 0.6787 | 1 |
Echinococcus granulosus | cadherin EGF LAG seven pass G type receptor | 0.0447 | 0.3057 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0447 | 0.3057 | 0.4505 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0967 | 0.6787 | 0.6787 |
Schistosoma mansoni | hypothetical protein | 0.0447 | 0.3057 | 0.4505 |
Loa Loa (eye worm) | latrophilin receptor protein 2 | 0.0447 | 0.3057 | 0.3057 |
Loa Loa (eye worm) | isocitrate dehydrogenase | 0.0085 | 0.0452 | 0.0452 |
Echinococcus granulosus | GPCR family 2 | 0.0447 | 0.3057 | 1 |
Echinococcus multilocularis | isocitrate dehydrogenase 2 (NADP+) | 0.0085 | 0.0452 | 0.148 |
Echinococcus multilocularis | Ataxin 2, N terminal,domain containing protein | 0.0022 | 0.0003 | 0.001 |
Toxoplasma gondii | isocitrate dehydrogenase | 0.0085 | 0.0452 | 1 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0406 | 0.2759 | 0.2759 |
Brugia malayi | hypothetical protein | 0.0032 | 0.0073 | 0.0073 |
Echinococcus multilocularis | NADP dependent isocitrate dehydrogenase | 0.0085 | 0.0452 | 0.148 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0406 | 0.2759 | 0.2759 |
Echinococcus multilocularis | GPCR, family 2 | 0.0447 | 0.3057 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0022 | 0.0003 | 0.0005 |
Brugia malayi | Isocitrate dehydrogenase | 0.0085 | 0.0452 | 0.0452 |
Schistosoma mansoni | tar DNA-binding protein | 0.0406 | 0.2759 | 0.4065 |
Schistosoma mansoni | tar DNA-binding protein | 0.0406 | 0.2759 | 0.4065 |
Loa Loa (eye worm) | hypothetical protein | 0.0049 | 0.0199 | 0.0199 |
Brugia malayi | hypothetical protein | 0.0049 | 0.0199 | 0.0199 |
Plasmodium vivax | isocitrate dehydrogenase [NADP], mitochondrial, putative | 0.0085 | 0.0452 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0447 | 0.3057 | 0.4505 |
Brugia malayi | N-terminal motif family protein | 0.0194 | 0.1238 | 0.1238 |
Trypanosoma cruzi | isocitrate dehydrogenase, putative | 0.0085 | 0.0452 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0406 | 0.2759 | 0.4065 |
Brugia malayi | RNA binding protein | 0.0406 | 0.2759 | 0.2759 |
Brugia malayi | Latrophilin receptor protein 2 | 0.0447 | 0.3057 | 0.3057 |
Loa Loa (eye worm) | hypothetical protein | 0.0194 | 0.1238 | 0.1238 |
Trypanosoma cruzi | isocitrate dehydrogenase [NADP], mitochondrial precursor, putative | 0.0085 | 0.0452 | 1 |
Echinococcus multilocularis | NADP dependent isocitrate dehydrogenase | 0.0085 | 0.0452 | 0.148 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.1414 | 1 | 1 |
Echinococcus granulosus | NADP dependent isocitrate dehydrogenase | 0.0085 | 0.0452 | 0.148 |
Brugia malayi | Cytochrome P450 family protein | 0.0027 | 0.004 | 0.004 |
Echinococcus multilocularis | NADP dependent isocitrate dehydrogenase | 0.0085 | 0.0452 | 0.148 |
Leishmania major | isocitrate dehydrogenase [NADP], mitochondrial precursor, putative | 0.0085 | 0.0452 | 1 |
Brugia malayi | isocitrate dehydrogenase | 0.0085 | 0.0452 | 0.0452 |
Toxoplasma gondii | isocitrate dehydrogenase | 0.0085 | 0.0452 | 1 |
Plasmodium falciparum | isocitrate dehydrogenase [NADP], mitochondrial | 0.0085 | 0.0452 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0967 | 0.6787 | 0.6787 |
Trypanosoma brucei | isocitrate dehydrogenase, putative | 0.0085 | 0.0452 | 1 |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.0027 | 0.004 | 0.004 |
Mycobacterium tuberculosis | Probable isocitrate dehydrogenase [NADP] Icd1 (oxalosuccinate decarboxylase) (IDH) (NADP+-specific ICDH) (IDP) | 0.0085 | 0.0452 | 0.5 |
Brugia malayi | TAR-binding protein | 0.0406 | 0.2759 | 0.2759 |
Echinococcus granulosus | diuretic hormone 44 receptor GPRdih2 | 0.0447 | 0.3057 | 1 |
Loa Loa (eye worm) | TAR-binding protein | 0.0406 | 0.2759 | 0.2759 |
Loa Loa (eye worm) | hypothetical protein | 0.1414 | 1 | 1 |
Brugia malayi | calcium-independent alpha-latrotoxin receptor 2, putative | 0.0447 | 0.3057 | 0.3057 |
Echinococcus granulosus | tar DNA binding protein | 0.0406 | 0.2759 | 0.9024 |
Schistosoma mansoni | hypothetical protein | 0.0447 | 0.3057 | 0.4505 |
Loa Loa (eye worm) | hypothetical protein | 0.0447 | 0.3057 | 0.3057 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
AC50 (functional) | PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp1a2 Compounds with AC50 equal or less than 10 uM are considered active | ChEMBL. | No reference | |
AC50 (functional) | PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp3a4 Compounds with AC50 equal or less than 10 uM are considered active | ChEMBL. | No reference | |
AC50 (functional) | PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2d6 Compounds with AC50 equal or less than 10 uM are considered active | ChEMBL. | No reference | |
AC50 (functional) | PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c9 Compounds with AC50 equal or less than 10 uM are considered active | ChEMBL. | No reference | |
AC50 (functional) | = 11.22018454 uM | PUBCHEM_BIOASSAY: Cytochrome panel assay with activity outcomes. (Class of assay: other) Panel member name: p450-cyp2c19 Compounds with AC50 equal or less than 10 uM are considered active | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Potency (functional) | 112.2018 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.